Charlotte's Web Holdings is participating as a CBD provider supporting the treatment of senior oncology patients under the newly announced landmark pilot program by the Center for Medicare and Medicaid Innovation (CMMI). For the first time, seniors living with cancer will gain access to science-backed CBD products with reimbursement through Medicare and Medicaid, creating a new model of care that prioritizes personalization, accessibility, and affordability. Through CMMI, this initiative represents a transformative moment in senior healthcare policy, introducing long-awaited flexibility and optionality for patients and providers seeking therapeutic hemp products.
Charlotte's Web will offer a set of products to address oncology patient needs early in 2026 through a secure online healthcare portal. The platform combines eCommerce with advanced data security to protect patient and physician information and is a continuing expansion to the Company's established medical channel business. This initiative introduces long-awaited optionality, with room for future product expansion.
"Charlotte's Web is proud to participate in the CMMI program to bring trusted CBD options to underserved seniors battling cancer," said CEO Bill Morachnick. "Charlotte's Web was founded to help Charlotte Figi, whose medically challenging life became a CBD success story. Her journey inspired research, opened doors to access, and changed perceptions about the therapeutic benefits of CBD around the globe. The Company made a promise to Charlotte, her mother Paige, and the millions who followed her: to set the standard for the entire industry by leading with quality, consistency, and science. As the CBD market leader and a trusted partner throughout the country among healthcare practitioners, this initiative marks a historic step forward, uniquely positioning Charlotte's Web to expand access to safe, non-intoxicating hemp CBD products through existing pathways. We thank the administration, CMMI, and all key stakeholders for their vision and persistence in making this possible."
Registration for the initiative is available at the link here.
Announced earlier this year, Charlotte's Web Scientific Advisory Board (SAB) will play a critical role in guiding its program, ensuring it reflects the Company's commitment to scientific rigor, clinical validation, and ethical responsibility. Comprised of interdisciplinary experts, the SAB advises on product integrity, patient and provider education, and long-term innovation strategies.
"Scientific rigor underpins every aspect of this program. With more than a decade of consumer use and extensive safety studies, Charlotte's Web integrates real-world evidence, patient-reported outcomes, and clinical insights into its R&D process to ensure products are safe and effective," said Dr. Marcel Bonn-Miller, Chief Scientific Officer at Charlotte's Web.
For more information:
Charlotte's Web Holdings
charlottesweb.com
